Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Scientists at West Virginia University publish research in breast cancer
October 16th, 2008
"Tumor marker cancer antigen (CA) 27.29 and combined [F-18]-fluorodeoxyglucose positron emission tomography (PET)/computed tomography (CT) scans are used to follow up response to treatment and disease progression In patients with metastatic breast cancer (MBC). Recently, circulating tumor cell testing (CTC) has been used in this context," investigators in the United States report. "It is not known if 1 of the 3 tests can be a surrogate for another. We analyzed a database of 35 patients with MBC. There were 173 time points (>= 6 weeks apart) when >= 2 of these tests were performed. Correlation among all the 3 tests was statistically analyzed. Results of PET/CT...
Source: Women's Health Weekly (2008-10-16)
|
